Michael Lisjak

Mike Lisjak became the company's Chief Regulatory Officer upon his promotion on September 29th, 2020 and continues to serve as the Senior Vice President for Business Development at Cyclo Therapeutics, Inc. He brings 25 years of Regulatory Strategy and Operations expertise within the biopharmaceutical and consulting industries for multiple therapeutic areas including cardiovascular, metabolic, neuroscience and pain and inflammation. Core skills include strategic planning, negotiating and influence, customer focus, and commercial awareness.

Prior to joining Cyclo Therapeutics, Inc., Mr. Lisjak was the Director of Global Reg Affairs at Sanofi leading the Endocrinology and Neuromuscular Rare Disease Area, which then led to a new role as the Head of Global Regulatory Affairs for Established Products and Global Health. Proceeding Sanofi, Mike served as the Global Regulatory Services Lead for Accenture’s Life Sciences group accountable for the growth and strategic oversight for Accenture’s global regulatory offerings, capabilities and go-to-market strategy. Before Accenture, he held multiple leadership roles at Pfizer and Wyeth with responsibility for developing, maintaining and directing global regulatory strategies and resources in the provision of regulatory guidance and deliverables as well as to ensure optimal regulatory interactions with global/regional Health Authorities. Additionally, Mike supported and delivered formal due diligence assessments for priority business development activities as well as led multiple business initiatives to deliver on-time efficiency solutions through assessment and implementation.

Mr. Lisjak is a Pittsburgh, PA native and currently resides with his family in Greenwich, CT. He holds a Bachelor of Science degree from Rochester Institute of Technology in biology and environmental studies.